Guides to Israel's cannabis market

What visitors need to know about cannabis in Israel — why foreign medical licences aren't recognised, whether you can bring your own, and how recreational possession is actually treated.

A clear breakdown of what medical cannabis really costs in Israel — licence fees, HMO charges, per-product pharmacy pricing, who gets funded treatment, and how to budget for a month.

A step-by-step guide to obtaining a medical cannabis permit in Israel — who can prescribe, how the Health Ministry's process works, what it costs and how long it takes.

Chronic pain is the single largest indication for medical cannabis in Israel. How access works, what pain specialists think, and what the outcome data shows.

How medical cannabis is used for PTSD in Israel — the scale of treatment, full reimbursement for combat-related cases, and the live debate over efficacy that prompted a Health Ministry review.

Which medical conditions can qualify for a cannabis licence in Israel — the approved indications across oncology, pain, neurology, gastroenterology and mental health, and how the 2024 reform changed the rules.

How Israel's cannabis decriminalisation actually works — the 2018–2019 reform, the fine schedule for personal possession, repeat-offence escalation, and what remains a criminal offence.

A clear answer to whether cannabis is legal in Israel — medical use, recreational use, decriminalised personal possession, and what's still a crime, as of 2026.

A chronological timeline of Israel's medical cannabis programme — from the first approvals in 1992 through per-product pricing, the 2024 HMO reform, and the 2025 expansion of specialist authority.

Where recreational cannabis legalisation stands in Israel — the failed bills, the politics that keep stalling reform, and why decriminalisation happened but legalisation hasn't.

A profile of IM Cannabis — the Nasdaq-listed operator's 2025 results, its sale of the European business, and its refocus on Israel and a possible US entry.

A profile of InterCure and its Canndoc subsidiary — Israel's largest licensed cannabis producer — covering its model, 2025 financials, stock listings and strategy.

A factual overview of the publicly listed Israeli cannabis companies, how to access them, and the sector-specific risks — not investment advice.

Why Israel — despite world-class research and pharmaceutical standards — is a net cannabis importer rather than an export powerhouse, and which companies actually export.

The universities, centres and clinical programmes that make Israel a world leader in cannabis research — from the Hebrew University's MCCR to the Technion's labs.

How Israeli chemist Raphael Mechoulam isolated THC, discovered the body's own cannabinoids, and made Israel the founding home of modern cannabis science.

A plain-English guide to the endocannabinoid system — the body's own cannabinoid network, much of it discovered through Israeli research — and why it matters for medical cannabis.

What the 'entourage effect' means — the idea, coined by Israeli researchers, that cannabis compounds work better together than in isolation — and what the evidence actually says.

The size and value of Israel's medical cannabis market — revenue figures, the legal-versus-illicit gap, and what the numbers mean for the sector's growth potential.

Israel's medical cannabis patient numbers — the decade of growth to a 2024 peak, the first-ever decline after the HMO reform, and what's driving the trend.

Where Israel's medical cannabis actually comes from — domestic cultivation versus imports, Canada's dominant role, and why supply is so exposed to trade policy.

How Israel's cannabis market compares to Germany, Canada and the US — small in volume, outsized in research influence, and a net importer in a competitive global trade.